SEC	Form	4			
		_	_	_	_

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

٦

Ī

Washington, D.C. 20549

							V	Vashi	ington, D.C. 2	0549					OMB	APPRO	VAL
Section obligat	this box if no lo n 16. Form 4 or ions may contir tion 1(b).	Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940						OMB Number: 3235- Estimated average burden hours per response:			3235-0287 n 0.5					
transac contrac the pur securit to satis conditi	rchase or sale of	pursuant to a written plan for of equity that is intended we defense															
1. Name and Address of Reporting Person [*] Lin Elizabeth Yeu						2. Issuer Name and Ticker or Trading Symbol <u>Tarsus Pharmaceuticals</u> , <u>Inc.</u> [TARS]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
	RSUS PHAI	irst) RMACEUTICA ANYON ROAD	1 () () () () () () () () () (60		3. Date of Earliest Transaction (Month/Day/Year) below							below)				
(Street) IRVINE			92618		4.1	Line)						e) ✔ Form f	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S		(Zip)														
		Tab	ole I - Nor	ו-Deriv	vativ	e Se	curities	s Ac	quired, D	isposed	of, or Be	neficial	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/E				Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		nt of s ally following a	Form (D) or	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	Amour	t (A) o (D)	r Price	Transact (Instr. 3 a				
		-							uired, Dis , options	•	•		Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,			Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5) 9. Numl Securit Securit Owned Followi Reporte Transac (Instr. 4		ve Ownersi ies Form: ially Direct (E or Indire ng (I) (Instr. ed		D) Beneficial Ownership oct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$46.21	11/04/2024			А		41,074		(1)	11/03/203	Common Stock	41,074	\$0	41,074		D	
Restricted Stock Units	(2)	11/04/2024			Α		27,278		(3)	(3)	Common Stock	27,278	\$0	27,27	8	D	

Explanation of Responses:

1. Option granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

Remarks:

/s/ Scott Sieckert, Attorney-in-

Fact

** Signature of Reporting Person Date

11/06/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.